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The chicken anemia virus-derived protein Apoptin in-
duces apoptosis specifically in human tumor and trans-
formed cells and not in normal, untransformed cells.
The cell killing activity correlates with a predominantly
nuclear localization of Apoptin in tumor cells, whereas
in normal cells, it is detected mainly in cytoplasmic
structures. To explore the role of nuclear localization
for Apoptin-induced cell death in tumor cells, we em-
ployed a mutagenesis strategy. First, we demonstrated
that the C terminus of Apoptin contains a bipartite-type
nuclear localization signal. Strikingly, further investi-
gation showed that Apoptin contains two different do-
mains that induce apoptosis independently, and for
both domains, we found a strong correlation between
localization and killing activity. Using inhibitors, we
ruled out the involvement of de novo gene transcription
and translation and further showed that Apoptin itself
does not have any significant transcriptional repression
activity, suggesting that Apoptin exerts its effects in the
nucleus by some other method. To determine whether
nuclear localization is sufficient to enable Apoptin to
kill normal, untransformed cells, we expressed full-
length Apoptin fused to a heterologous nuclear localiza-
tion signal in these cells. However, despite its nuclear
localization, no apoptosis was induced, which suggests
that nuclear localization per se is not sufficient for
Apoptin to become active. These studies increase our
understanding of the molecular pathway of Apoptin and
may also shed light on the mechanism of cellular
transformation.
Apoptin is a protein derived from chicken anemia virus
(CAV)1 (1), an avian pathogen that causes depletion of thymo-
cytes and erythroblastoid cells in young chickens via the induc-
tion of apoptosis. This protein, one of three encoded by the viral
genome of CAV, was shown to reproduce the cell killing activity
in cultured cells (2). Apoptin has been shown to induce apo-
ptosis not only in transformed chicken cells but also in human
tumor cell lines derived from a wide variety of tissue origins,
including tumor cells with common lesions such as loss of p53
or overexpression of Bcl-2, with no known exceptions to date (3,
4). Remarkably, however, all normal untransformed cells
tested were resistant (5, 6). These characteristics make
Apoptin a promising candidate for anti-tumor therapy, which is
often thwarted by genetic lesions that render tumor cells re-
sistant (7–9). Dissecting the mechanism of Apoptin-induced
apoptosis may be helpful not only for the use of Apoptin as an
anti-tumor agent but may also provide information about the
characteristics of the transformation-specific state of a cell.
The mechanism of action for Apoptin is still unclear, but a
clue may be found in its localization. In transformed and tumor
cells, Apoptin is predominantly found in the nucleus, whereas
in untransformed cells Apoptin is mainly localized to the cyto-
plasm (5). A further indication that localization may be impor-
tant was obtained from studies in which Apoptin was tran-
siently co-expressed with the strongly transforming SV40 large
T antigen in previously untransformed cells. Remarkably, this
treatment redirected Apoptin to the nucleus of normal diploid
cells and simultaneously sensitized these cells to Apoptin-
induced apoptosis (10). Furthermore, Apoptin was found to
translocate to the nucleus and induce cell death in primary
cells from certain cancer-prone individuals, but only after UV
irradiation (11), further strengthening the correlation between
localization and cell death.
The amino acid sequence of Apoptin (see Fig. 1) contains two
basic stretches constituting putative nuclear localization sig-
nals (NLS) and a stretch of alternating isoleucines and leucines
that resembles a nuclear export signal (12, 13). Deletion of the
second of the two putative NLSs of Apoptin resulted in its
diffuse localization all over the cytoplasm, with some protein
still present in the nucleus (4). This truncated form of Apoptin
had a reduced cell killing activity, suggesting that nuclear
localization may be required for apoptosis induction. However,
such a truncation could influence other aspects of the protein,
e.g. its folding, which could also alter its apoptosis activity.
Therefore it was essential to test more mutants of Apoptin.
In this study, we used mutagenesis to investigate further the
relationship between nuclear localization of Apoptin and its
cell killing activity. We determined the minimal region of
Apoptin required for nuclear localization and showed that this
region contains a bipartite-type NLS. Furthermore, we showed
that distinct parts of Apoptin have independent, intrinsic cell
killing activities and that for both domains, nuclear localiza-
tion is strongly correlated with induction of cell death. How-
ever, redirecting Apoptin into the nucleus of normal, untrans-
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formed cells by fusing it to a heterologous NLS did not result in
induction of apoptosis. Thus, nuclear localization appears to be
important but not sufficient for the tumor-specific cell killing
activity of Apoptin.
EXPERIMENTAL PROCEDURES
Plasmids—pCMV-VP3, encoding Apoptin, and pCMV-neo-Bam, the
empty control plasmid, have been described before (2, 14). pCMV-
Desmin encodes the muscle-specific cytoskeletal protein Desmin, which
has no apoptotic activity and is used as a negative control (5). Several
phGFP-S65T-derived plasmids expressing fusions of green fluorescent
protein (GFP) and parts of Apoptin have been generated. All of the
fusion proteins have GFP at the N terminus of Apoptin. A schematic
overview of all fusion constructs is given in Fig. 2. phGFP-S65T ex-
presses a variant of GFP from Aequorea victoria, which has been opti-
mized for human codon usage, and serine 65 has been mutated to
threonine to enhance the fluorescent signal (Clontech).
A DNA fragment encoding Apoptin was digested from pET16b-VP32
with NdeI/BamHI. This fragment was then digested with BsrI, result-
ing in fragments encoding Apoptin amino acids (aa) 1–69 and Apoptin
aa 70–121. These fragments were ligated with the appropriate linkers
in between the BsrGI and NotI sites C-terminal of GFP, generating
phGFP-VP3, phGFP-VP3 (1–69), and phGFP-VP3 (70–121). phGFP-
VP3 (111–121) was made by inserting a linker, which encodes a 4-aa
spacer (Pro-Gly-Ala-Gly) and aa 111–121 of Apoptin, in between the
BsrGI and NotI sites of phGFP-S65T. PCR fragments of Apoptin aa
80–121, 90–121, and 100–121 with overhanging BsrGI and NotI sites
were cloned into phGFP-S65T to generate the plasmids phGFP-VP3
(80–121), phGFP-VP3 (90–121), and phGFP-VP3 (100–121). All of the
plasmids were sequenced to confirm the correct reading frame of the
fusion proteins.
pCMV-NLS-VP3, encoding Apoptin fused to an SV40 large T-NLS
(PPKKKRKV), was generated by ligating a linker, with ATG start
codon and NLS, to the N terminus of an NdeI/BamHI fragment of
Apoptin. The resulting fragment was cloned into the BamHI site of
pCMV-neo-Bam. Similarly, the SV40 large T-NLS was fused to a NdeI/
BsrI fragment of Apoptin encoding aa 1–69, generating pCMV-NLS-
VP3 (1–69). phGFP-NLS was constructed by fusing the same NLS to
the C terminus of GFP. All of the plasmids were confirmed by
sequencing.
The mutant Ala086 was constructed by replacing aa 86–90 of
Apoptin with alanine residues. To this end, first, an Apoptin DNA was
constructed containing additional unique restriction enzyme sites that
allow for ease of cloning (sAPO). Then aa 86–90 of Apoptin were
exchanged by 5 alanine residues using a linker substitution strategy.
The Ala086 mutant and sAPO were sequenced and cloned in a modified
expression plasmid vector pIRESneo (Clontech) under the control of the
CMV promoter. pEGFP-N1 (Clontech) encodes enhanced GFP, which is
optimized for human codon usage and contains chromophore mutations
enhancing its fluorescence, under the control of the CMV promoter.
pGal4-YY1 encoding YY1 fused to the Gal4 DNA-binding domain
(BD) was a kind gift from R. Johnstone and Y. Shi (15). The reporter
plasmid 5xGal4-TK-Luc was a kind gift from E. Kalkhoven and con-
tains the luciferase gene under the regulation of the herpes simplex
virus TK promoter joined to 5xGal4-binding elements (16).
pcDNA3.1/mycHis/LacZ (Invitrogen) encodes LacZ with a Myc and His
tag attached to the C terminus, regulated by a CMV promoter. pFA-
CMV (Stratagene) contains the Gal4 BD upstream of a multiple cloning
site, under the regulation of a CMV promoter. A DNA fragment encod-
ing Apoptin was cloned into the multiple cloning site of pFA-CMV and
confirmed by sequencing (Baseclear). The resulting plasmid pFA-VP3
encodes a Gal4 BD fusion to Apoptin.
Expression and Purification of Proteins—The cloning, expression,
and purification of recombinant MBP-Apoptin protein and the control
protein MBP have been described (17). In short, the construct pMalT-
BVP3 encodes MBP-Apoptin, an N-terminal fusion of MBP to Apoptin,
separated by a flexible linker encoding 10 asparagine residues. The
construct pMalTB encodes MBP alone. Both proteins were expressed in
Escherichia coli and purified by standard methods.
Cell Culture, Transfection, and Microinjection Methods—The human
osteosarcoma cell lines Saos-2 and U-2 OS and the human normal
diploid skin fibroblast strain VH10 (up to passage 15) were grown in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf
serum, penicillin, and streptomycin (Invitrogen).
Saos-2 cells were grown on glass coverslips and transfected with 3 g
of DNA/well of a 6-well dish by the CaPO4 method as described (18).
VH10 cells, which were grown in Permanox chamber slides (Invitro-
gen), were transfected with FuGENE 6 (Roche Applied Science) accord-
ing to the manufacturer’s protocol. 2 g of DNA was transfected per
chamber.
For microinjections Saos-2 cells were cultured on glass-bottomed
microinjection dishes (MatTek Corporation) or in 35-mm dishes con-
taining glass Cellocate coverslips (Eppendorf). The cells were microin-
jected in the nucleus with DNA (50 ng/l in phosphate-buffered saline)
or in the cytoplasm with protein (3 mg/ml) using an Eppendorf micro-
injector with the injection pressure condition of 55 hPa. The cells were
co-injected with Dextran-rhodamine (molecular mass, 70 kDa; Molecu-
lar Probes) to be able to later identify injected cells.
Fluorescence Microscopy—Saos-2 cells were fixed with 1% formalde-
hyde in phosphate-buffered saline for 10 min, followed by 100% meth-
anol for 5 min, and finally 80% acetone for 2 min. VH10 cells were fixed
with 50% acetone, 50% methanol for 5 min. The slides were stored at
20 °C until further use. Immunocytochemical staining was performed
as described (19). GFP and GFP fusion proteins were detected by their
intrinsic fluorescent signal. Apoptin was detected either with the mouse
monoclonal antibody CVI-CAV-111.3, which recognizes an epitope lying
in the N terminus of Apoptin (5), or with the rabbit polyclonal antibody
R-VP3-C (19). Desmin was detected with mouse monoclonal antibody
33 (Monosan). Secondary antibodies were either conjugated to fluores-
cein isothiocyanate or rhodamine (Jackson ImmunoResearch Laborato-
ries). The chromatin was stained with 1 g of 2,4-diamidino-2-phenylin-
dole (DAPI)/ml. The cells were analyzed by fluorescence microscopy for
expression of the transfected protein. Nuclear morphology of those cells
expressing the transfected protein was analyzed by examining the
DAPI staining, which indicates the apoptotic state. Namely, during
apoptosis, the whole cell has shrunken, the chromatin is condensed, the
nucleus is often fragmented, and finally DAPI staining is lost because of
fragmentation of the DNA. The statistics were performed using Stu-
dent’s t test. Images of representative cells were made with either a
standard photocamera or a digital video camera connected to a fluores-
cence microscope AX70 (Olympus) and AnalySIS software.
Transcription and Translation Inhibition—For the transcription/
translation inhibition experiments, we used one RNA synthesis inhib-
itor, actinomycin D (Sigma), and two protein synthesis inhibitors, pu-
romycin (Sigma) and emetine (Sigma). Numerous studies have shown
that the inhibition of RNA and protein synthesis alone can directly
trigger apoptosis in various cell types (20–22). Therefore, the cytotox-
icity of each inhibitor used in our study was first analyzed by 24-h
incubation at a dose range of 0, 5, 10, 20, 40, and 80 g/ml concentra-
tion. On the basis of cell killing curves following 24 h of incubation, the
subtoxic dosage of each inhibitor was then determined at 10 g/ml for
all three inhibitors. To determine the effective transcription and trans-
lation inhibition by each inhibitor, Saos-2 cells were injected in the
nucleus with the plasmid pEGFP-N1 (50 ng/l) expressing enhanced
GFP, which was used as an indicator. To assess the effect of the
inhibitors on Apoptin, Saos-2 cells were incubated for 3 h with each
inhibitor before and for a further 6 h after microinjection in the cyto-
plasm with the recombinant proteins MBP-Apoptin or MBP (3 mg/ml).
Dextran-rhodamine (1 mg/ml) was co-injected as a marker. The cells
were fixed 6 h after microinjection as described above. The expression of
GFP, the presence of MBP-Apoptin or MBP, and nuclear morphology
were analyzed by fluorescence microscopy.
Luciferase Reporter Assay—U-2 OS cells were plated in 6-well plates
and transfected with FuGENE 6 and with 1 g/well 5xGal4-TK-Luc as
the reporter plasmid, pcDNA3.1/mycHis/LacZ at 100 ng/well as an
internal control, and Gal4 BD plasmids at 200 ng/well. Two days later,
the cells were lysed in reporter lysis buffer (Promega), and the lysates
were assayed for luciferase activity and for -galactosidase activity
according to the manufacturer’s protocol (Promega).
RESULTS
Apoptin Contains a Functional, Bipartite-type NLS—Previ-
ous work has suggested that the nuclear localization of Apoptin
may be correlated to its killing activity in tumor cells. In this
study, we first set out to delineate the elements involved in
nuclear localization of Apoptin. Apoptin contains two se-
quences that resemble NLSs based on the presence of positively
charged aa, namely aa 82–88 (NLS1) and aa 111–121 (NLS2)
(Fig. 1). Deletion of aa 111–121 has already been shown to
result in decreased nuclear localization, suggesting that NLS22 M. H. M. Noteborn, unpublished data.
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is involved in nuclear targeting (4). To test whether aa 111–121
of Apoptin can act independently as an NLS, this part was
N-terminally fused to GFP, creating GFP-Apoptin(111–121)
(Fig. 2A). An SV40 large T-derived NLS fused to the C terminus
of GFP (GFP-NLS) was used as a positive control. The human
osteosarcoma cell line Saos-2 was transfected with the GFP
fusion constructs, and cells were fixed and analyzed by fluores-
cence microscopy for protein expression and localization in
healthy cells. Wild type (wt) GFP was localized diffusely
throughout the whole cell. In contrast, GFP-NLS was clearly
located in the nucleus. However, GFP-Apoptin(111–121) was
found dispersed throughout the whole cell, similar to what was
seen with wt GFP, although GFP-Apoptin(111–121) did show a
more punctate staining in the cytoplasm than did wt GFP (Fig.
2B). These data indicate that aa 111–121 (NLS2) of Apoptin are
not sufficient to confer nuclear localization.
To resolve the minimal requirements for nuclear localization
of Apoptin in tumor cells, we made more N-terminal GFP
fusions with fragments of Apoptin (Fig. 2A) and determined
their localization. Fusion of aa 70–121 or 80–121, containing
both putative NLSs, effectively redirected GFP to the nucleus,
whereas fusion of aa 90–121 or 100–121, which lack NLS1, did
not. These data suggest that both NLSs are needed for efficient
nuclear targeting. Fusion of GFP with aa 1–69 of Apoptin,
which lacks both NLSs, almost completely abrogated nuclear
localization (Fig. 2C). These data indicate that the N-terminal
half of Apoptin is able to change the localization of GFP from
being diffused throughout the whole cell to being predomi-
nantly cytoplasmic, which suggests that this part of Apoptin
possesses either nuclear export or cytoplasmic retention activ-
ity. To test further the requirement for both NLSs for nuclear
localization, we mutated aa 86–90 (KKRSC) to alanines, cre-
ating the mutant Ala086. Ala086 exhibited a partial but sig-
nificant impairment of nuclear localization, together with the
formation of aggregates in the cytoplasm (Fig. 2D). These data
indicate that the NLSs of Apoptin are indeed interdependent,
consistent with them functioning as a bipartite-type NLS char-
acterized by two basic domains separated by a spacer (23).
Nuclear Localization Strongly Correlates with Apoptotic Ac-
tivity—We observed that early after transfection (2–3 days)
Apoptin is mainly localized in the nucleus of Saos-2 cells but
hardly induces apoptosis, which is consistent with previous
results (4, 24). This implies that Apoptin enters the nucleus
before the onset of cell death. Here, we examined further the
relationship between the localization of Apoptin and its
apoptotic activity. To this end, the human osteosarcoma cell
line Saos-2 was transfected with the GFP fusion constructs
described above, along with GFP fused to wt Apoptin as a
positive control. Five days post-transfection, the cells were
fixed and analyzed by fluorescence microscopy for expression of
the proteins and for apoptosis induction as determined by
nuclear morphology. At this time point, the majority of cells
expressing Apoptin will have become apoptotic (4, 19, 24).
We first examined whether fusion to GFP had any effect on
the apoptotic activity of Apoptin and found that the full-length
Apoptin protein fused to GFP-induced apoptosis to the same
extent as did wt Apoptin in Saos-2 cells (data not shown). GFP
by itself was mainly found in a diffuse pattern throughout the
cell and only resulted in a background level of apoptosis induc-
tion (Fig. 3A) similar to that caused by the negative control
protein, Desmin, which does not induce apoptosis (5, 24) (Fig.
4). GFP-Apoptin(1–69) induced cell death only slightly, albeit
significantly (p 0.01) (Fig. 3A). In contrast, GFP-Apoptin(70–
121) displayed a more robust cell killing activity (Fig. 3A).
However, apoptosis induction was markedly reduced as com-
pared with GFP-Apoptin. These results show that the C-termi-
nal half of Apoptin and, to a lesser extent, the N-terminal half
both have intrinsic apoptotic activity, albeit less than full-
length Apoptin.
To delineate further the C-terminal apoptosis domain, we
determined the cell killing activity of smaller fragments of
Apoptin fused to GFP. Whereas expression of GFP-
Apoptin(100–121) did not result in significant cell death, GFP-
Apoptin(90–121) caused 12% of the cells to undergo apoptosis,
which is moderate but significantly higher (p  0.01) than the
effect of wt GFP (Fig. 3A). In contrast, GFP-Apoptin(80–121)
caused a robust level of apoptosis (30%), although less than
that induced by GFP-Apoptin (Fig. 3A). Thus, aa 80–121 are
sufficient to induce the cell death conferred by the C-terminal
apoptosis domain of Apoptin.
Next, we compared the cell killing activity of the different
mutants to their localization. The localization was determined
in cells not yet displaying apoptotic morphology, because in
apoptotic cells hardly any distinction can be made between the
nucleus and the cytoplasm. In apoptotic cells, Apoptin largely
co-localizes with the DNA (data not shown; Refs. 4, 19, and 24).
Strikingly, as shown in Fig. 3 (A and B), the mutants conferring
the strongest nuclear localization, namely GFP-Apoptin(70–
121) and (80–121), also induced the highest amounts of cell
death. Furthermore, we examined the cell killing activity of the
mutant Ala086, in which part of the bipartite NLS is disrupted.
Ala086 not only displayed impaired nuclear localization but
also significantly reduced apoptosis activity (p  0.05) (Fig. 3,
C and D). Taken together, these data show that a strong nu-
clear localization correlates with a more robust cell killing
activity of parts of Apoptin, and, moreover, that a mutation
that impairs nuclear localization of Apoptin also diminishes its
cell killing activity.
Directing the N-terminal Domain to the Nucleus Greatly En-
hances Its Cell Killing Activity—We were surprised to find that
two separate domains of Apoptin were both able to kill tumor
cells. However, the N-terminal domain, aa 1–69, induced much
less apoptosis than the C-terminal domain, aa 80–121, or than
wt Apoptin. Based on the results shown thus far, implying that
induction of apoptosis depends on nuclear localization, this
result may be explained by the mainly cytoplasmic localization
of the N-terminal domain. Therefore, we generated a mutant
encoding aa 1–69 of Apoptin fused at its N terminus to a
heterologous NLS. Expression of this protein in Saos-2 cells not
only resulted in increased nuclear localization but also in a
stronger induction of apoptosis (Fig. 4), albeit less than wt
Apoptin. The fact that nuclear targeting enhanced the cell
killing activity of the N-terminal domain again suggests that
nuclear localization is involved in the ability of Apoptin to
induce efficient apoptosis. More importantly, both the N- and
C-terminal parts of Apoptin contain a domain conferring sig-
nificant apoptotic activity, although both domains appear to be
necessary for full potency.
Enforced Nuclear Localization of Apoptin in Normal Diploid
Cells Does Not Cause Apoptosis—Based on the results men-
tioned above, nuclear localization appears to be a prerequisite
for robust apoptosis induction by Apoptin in human tumor
cells. Because Apoptin is predominantly found in the cytoplasm
FIG. 1. Sequence of Apoptin. Amino acid residues are depicted in
single-letter codes. A putative nuclear export signal located at aa 33–46
is underlined with a single line. Two putative nuclear localization
signals at aa 82–88 (NLS1) and 111–121 (NLS2) are double underlined.
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in untransformed cells and does not induce apoptosis (5), it was
possible that Apoptin does not kill these cells solely because it
is in the wrong compartment to do so. Therefore, we investi-
gated whether enforced nuclear localization of Apoptin in nor-
mal diploid cells would result in apoptosis induction. To this
end, we generated a construct (NLS-Apoptin) consisting of the
Apoptin gene fused N-terminally to a heterologous NLS (Fig.
5). NLS-Apoptin was transiently expressed in normal human
skin fibroblasts, called VH10 (25). In these cells, NLS-Apoptin
was predominantly detected in the nucleus in a diffuse pattern.
In contrast, wt Apoptin was found mainly in the cytoplasm as
granular or thready structures (Fig. 5). However, despite its
nuclear localization, NLS-Apoptin was unable to induce apo-
ptosis in VH10 cells, just as wt Apoptin failed to do so (Fig. 5).
We have shown before that the slight induction of apoptosis by
wt Apoptin in normal cells is not significantly different from
that induced by Desmin, a nonapoptotic cytoskeletal protein,
and can be considered as background (5). The data presented
here imply that in addition to nuclear localization, other events
are necessary for Apoptin to induce cell death.
Apoptin-induced Apoptosis Does Not Require de Novo Gene
Transcription and Translation—The strong correlation be-
tween nuclear localization and cell death activity of Apoptin
suggests that Apoptin acts in the nucleus. Moreover, we have
found that Apoptin directly interacts with DNA in vitro (17).
Therefore, we set out to determine whether transcriptional
activation of genes is involved in Apoptin-induced cell death. To
evaluate the requirements for both de novo RNA and protein
synthesis, we used one RNA synthesis inhibitor, actinomycin
D, and two protein synthesis inhibitors, puromycin and eme-
tine. After determining the subtoxic dosages for each inhibitor
(10 g/ml; data not shown), we assessed the effectiveness on
transcription and translation processes. Saos-2 cells were in-
cubated with each inhibitor for 3 h, microinjected with
pEGFP-N1 plasmid, and then incubated for a further 6 h with
the inhibitors. As determined by fluorescence microscopy, the
expression of GFP was reduced to nondetectable levels in the
presence of each inhibitor, whereas GFP was highly expressed
in nontreated cells (Fig. 6A). These results indicate that at the
given concentration and time point, all inhibitors were effective
in blocking the processes of de novo gene transcription and
translation.
Next, we examined the effect of RNA and protein synthesis
inhibitors on the cell killing activity of Apoptin. Because the
inhibitors would not allow expression of Apoptin from a trans-
fected plasmid, we used instead a recombinant Apoptin protein
fused on its N terminus to MBP, shown previously to exhibit
FIG. 2. Localization of different Apoptin mutants. A, schematic overview of plasmids. The GFP moiety is depicted as a light gray bar,
Apoptin is a white bar, the putative NLSs within Apoptin are dark gray bars, and the alanine replacement is indicated with the letter a. The
numbers indicate amino acid residues within the Apoptin moiety. B, Saos-2 cells fixed 2 days post-transfection, expressing GFP (a and d), GFP-NLS
(b and e), and GFP-Apoptin(111–121) (c and f). GFP signal (a–c) or nuclear staining with DAPI (d–f) is shown. C, Saos-2 cells fixed 5 days
post-transfection. The cells are expressing GFP fused to full-length Apoptin (a and g), or to Apoptin amino acids 1–69 (b and h), 70–121 (c and i),
80–121 (d and j), 90–121 (e and k), and 100–121 (f and l). GFP signal (a–f) and nuclear staining with DAPI (g–l) are shown. D, Saos-2 cells fixed
at day 4 post-transfection, expressing Ala086. Staining for Ala086 with anti-Apoptin RVP3-C (a) or nuclear staining with DAPI (b). All of the
images were made of representative cells; the scale bars correspond to 10 m. E, comparison of amino acid sequence of bipartite NLSs from Xenopus
nucleoplasmin, human HIF2, and Apoptin. The numbers indicate amino acid residues.
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the same tumor-specific cell killing as wt Apoptin.3 Saos-2 cells
were incubated with each inhibitor as described above and
injected with either MBP-Apoptin protein or MBP as a negative
control. Noninjected cells were analyzed as a control for possi-
ble apoptosis induction by inhibitor treatment. MBP-Apoptin
induced almost equal levels of apoptosis 6 h after microinjec-
tion either in the presence or in the absence of each inhibitor
(Fig. 6B), indicating that such inhibitors had no effect on the
ability of Apoptin to kill. Treatment with subtoxic levels of
cycloheximide (20 g/ml), another inhibitor of protein synthe-
sis, gave similar results (data not shown). These data suggest
that de novo gene and protein expression are not required for
the induction of apoptosis by Apoptin in tumor cells.
Apoptin Does Not Behave as a Transcriptional Repressor—
Having ruled out the involvement of transcriptional activation
in Apoptin-induced apoptosis, we next examined the possibility
that Apoptin functions as a repressor of transcription. To this
end, we fused full-length Apoptin N-terminally to the BD of
Gal4 and determined its effects in U-2 OS osteosarcoma cells
on a co-transfected luciferase reporter plasmid containing five
Gal4-binding sites preceding the herpes simplex virus TK-
promoter. This promoter is known to result in a relatively high
basal level of luciferase activity and can therefore be used to
study repression (26). A known enhancer of transcription,
VP16, was shown to increase luciferase activity as expected
(data not shown). Gal4-Apoptin did not significantly differ from
the control plasmid expressing only the Gal4 BD, whereas
Gal4-YY1, a known transcriptional repressor (26), was able to
decrease the basal transcription levels 5-fold (Fig. 7). These
data show that, under these conditions, Apoptin itself does not
act as a transcriptional repressor. Taken together, our results
are consistent with the hypothesis that Apoptin exerts its ef-
fects in the nucleus but in a manner independent of transcrip-
tional activation and not involving direct transcriptional
repression.
DISCUSSION
Nuclear Localization Strongly Correlates with the Cell Kill-
ing Activity of Apoptin—Previously, we have shown that
Apoptin kills tumor and transformed cells, where it is mainly
nuclear, but does not induce apoptosis in untransformed, nor-
mal cells, where it is found predominantly in the cytoplasm.
This observation suggested that the underlying mechanism of
tumor-specific killing by Apoptin involves nuclear localization
of the protein (5). Here, we investigated the correlation be-
tween nuclear localization and cell killing activity by mutagen-
esis of Apoptin. Surprisingly, we found that both the N- and
C-terminal halves of Apoptin have intrinsic apoptotic activity,
albeit reduced compared with full-length Apoptin. This sug-
gests that there are two independent apoptotic domains within
the protein. However, using computer analysis, no homology
between these domains could be found within their sequence or
in their predicted secondary structure. Another possibility is
the presence of one large apoptotic domain extending from the
N terminus into the C terminus, of which the complete length
is needed for full apoptotic activity.
Furthermore, we show here that nuclear localization of var-
ious Apoptin mutants was strongly correlated with apoptosis
induction. GFP fusions of C-terminal parts of Apoptin that still
permitted a profoundly nuclear localization also resulted in
3 Zhang, Y.-H., Leliveld, S. R., Kooistra, K., Molenaar, C., Rohn, J. R.,
Tanke, H. J., Abrahams, J. P., and Noteborn, M. H. M. (2003) Exp. Cell
Res., in press.
FIG. 3. Apoptotic activity in correlation with the localization of several Apoptin mutants. A and B, Saos-2 cells were transiently
transfected with the indicated GFP fusions or GFP as a control, fixed 5 days later, and analyzed for protein expression and apoptosis induction by
fluorescence microscopy. C and D, Saos-2 cells were transfected with Ala086, full-length Apoptin (sAPO), or Desmin as a negative control, fixed
4 days later, and analyzed by immunofluorescence microscopy. A and C, apoptosis induction as determined by nuclear morphology. B and D,
localization in nonapoptotic cells. Given are the means of at least three (A and B) or two (C and D) independent experiments; in each experiment
at least 100 positive cells were scored. The error bars represent the standard deviations.
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robust cell killing activity. Apoptin aa 1–69 fused to GFP,
which localized to the cytoplasm, had only mild cell killing
activity. Nevertheless, fusion of Apoptin aa 1–69 to a heterol-
ogous NLS resulted in visible translocation to the nucleus and
markedly increased induction of apoptosis. Although these
data do not rule out the possibility that fusion to the NLS also
influences the structure of aa 1–69, thereby possibly enhancing
the apoptotic function, they strongly suggest a requirement for
nuclear localization. Furthermore, the mutant Ala086, which
disrupts part of the bipartite NLS, showed an increased cyto-
plasmic localization and a markedly reduced apoptotic activity.
Earlier, similar results were found when aa 111–121 of Apoptin
were deleted (4). Thus, partially preventing translocation to
the nucleus also diminishes the apoptotic activity of Apoptin in
tumor cells, making it quite likely that nuclear localization is a
cause rather than a result of apoptosis induction.
The data shown here also seem to indicate the possibility
that Apoptin activates more than one pathway resulting in
apoptosis, which may not be initiated all from within the nu-
cleus. The fact that GFP-Apoptin(1–69) induced mild apoptosis
suggests that Apoptin can also activate the apoptotic machin-
ery from the cytoplasm. However, this fact may also be ex-
plained by small, undetectable quantities of GFP-Apoptin(1–
69) being present and active in the nucleus or by untagged
contaminants, which can occur when expressing fusion pro-
teins, although double staining with an antibody against the
Apoptin moiety did not result in a significantly different stain-
ing pattern (data not shown). Nevertheless, even though the
nuclear pathway appears to be the most potent, a cytoplasmic
pathway for Apoptin-induced cell death cannot be excluded. In
support of this view, the tumor-specific cell killing protein
E4orf4 of adenovirus was recently shown to activate both a
cytoplasmic and a nuclear apoptosis pathway (27).
Apoptin Contains a Bipartite NLS in the C Terminus and
Cytoplasmic Localization Activity in the N Terminus—In this
study, the minimal domain required for nuclear localization of
Apoptin has been narrowed down to aa 80–121. This part was
sufficient to redirect GFP to the nucleus. Earlier work has
shown that deletion of NLS2 impaired nuclear localization (4).
Here, we have demonstrated that mutation of aa 86–90
(KKRSC) to alanines similarly inhibited nuclear translocation.
Taken together, these data confirm that the two putative
NLSs, one stretching from aa 82 to 88 and the other stretching
from aa 111 to 121, actually function as such. Moreover, both
stretches are required to obtain complete nuclear localization,
because deletion or mutation of either of the two NLSs resulted
in a diminished nuclear translocation. These data imply that
Apoptin contains a bipartite-type NLS. The classic example of
a bipartite NLS is the one defined for the protein nucleoplas-
min, which consists of two basic domains separated by a spacer
sequence of 10 amino acids. Other bipartite NLSs were found to
have similarly short spacer sequences, e.g. interferon regula-
tory factor and hnRNP K (28–30). However, a novel variant
was recently found in hypoxia-inducible factors that contain
distinctly longer spacer sequences of 19–31 amino acids (31).
Upon comparison of Apoptin with these sequences, we found
that the Apoptin NLS is most similar to the hypoxia-inducible
factor 2 bipartite NLS (Fig. 2E), both in conserved residues
FIG. 4. Apoptosis induction and nuclear localization of NLS-
Apoptin(1–69). Saos-2 cells were transiently transfected, fixed 5 days
later, and analyzed by immunofluorescence microscopy. A, percentage
cell death among cells expressing NLS-Apoptin(1–69), Apoptin, or
Desmin (negative control), as determined by nuclear morphology. B,
localization in nonapoptotic cells. The results are given as the means of
three independent experiments, and the error bars represent the stand-
ard deviations. In each experiment at least 100 cells were scored.
FIG. 5. NLS-Apoptin did not induce apoptosis in normal dip-
loid fibroblasts. VH10 cells fixed 4 days post-transfection were ana-
lyzed by immunofluorescence. A, apoptotic activity as determined by
nuclear morphology. B, localization in nonapoptotic VH10 cells. Shown
are the means of three independent experiments, in which at least 100
cells were scored. The error bars represent the standard deviations. C,
images of representative cells expressing Apoptin (a and b) or NLS-
Apoptin (c and d). The cells were stained with the antibody CVI-CAV-
111.3 (a and c) or with DAPI (b and d). The scale bar corresponds to 10
m.
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and spacing. Therefore, the Apoptin bipartite NLS may belong
to the same category as those found in hypoxia-inducible
factors.
Fusion with aa 1–69 of Apoptin redirected GFP predomi-
nantly to the cytoplasm. These data suggest that aa 1–69 of
Apoptin contain either a nuclear export signal or a domain
involved in cytoplasmic retention. The aa sequence of Apoptin
in fact contains a stretch of alternating isoleucines and leucines
resembling previously identified nuclear export signals of the
proteins PKI and Rev (32, 33). However, fusion of this partic-
ular part of Apoptin, aa 33–46, to the C terminus of GFP, did
not result in increased cytoplasmic localization (data not
shown). It is possible that other residues are required as well
for cytoplasmic localization. Conversely, it is also conceivable
that aa 1–69 of Apoptin contain a domain involved in retention
in the cytoplasm, perhaps through binding to another protein.
We are currently investigating both possibilities.
Apoptin-induced Cell Death Neither Requires Transcrip-
tional Activation nor Involves Direct Transcriptional Repres-
sion—The data mentioned above indicate that nuclear localiza-
tion of Apoptin is important for its cell killing activity. It is still
unknown how the presence of Apoptin in the nucleus would
result in cell death. Recently, we determined that recombinant
Apoptin protein binds to naked DNA in vitro in a non-sequence-
dependent manner,4 which, together with the importance of
nuclear localization for its activity, suggests that Apoptin may
play a role in the regulation of gene expression. However, in
this study, we show that de novo gene transcription and trans-
lation are not required for Apoptin-induced apoptosis, implying
that all downstream elements are already present in the cell.
When we performed similar experiments in nontransformed
VH10 fibroblasts, the transcription and translation inhibitors
did not enable MBP-Apoptin to induce cell death in these
normal cells, ruling out the possibility that tumor specificity is
determined by the presence of a labile inhibitor in normal cells
(data not shown).
DNA binding may also result in repression of transcription.
Notably, we have recently shown by electron microscopy that
Apoptin co-localizes with heterochromatin, which is predomi-
nantly transcriptionally inactive.4 Nevertheless, here, Apoptin
itself did not act as a transcriptional repressor in a reporter
assay. However, the in vitro model system tested here is not
entirely analogous to physiological conditions, alternatively,
there remains a formal possibility that fusion of Apoptin to the
Gal4 BD impairs its activity. Moreover, these experiments
cannot eliminate the possibility of involvement of transcrip-
tional repression via an indirect mechanism. For example,
Apoptin may bind to co-factors involved in repression and
tether them to the DNA, and such endogenous factors are in
limited supply in an overexpression system. Indeed, we have
recently found that Apoptin can bind to DEDAF, which has
been shown to act as a transcriptional repressor and to be
involved in apoptosis (34, 35).5
Nuclear Localization Is Not the Sole Determinant of the Tu-
mor Specificity of Apoptin—Previously we have shown that
Apoptin does not induce apoptosis in nontransformed cells,
where it is predominantly found in cytoplasmic structures (5).
We have noticed, however, that variations in transfection
methods and the condition of the cells can cause increased
translocation of Apoptin to the nucleus of normal cells. We have
not been able to pinpoint which factor(s) influence this out-
come, although methods that prevent prolonged presence of
ectopic DNA in the cytoplasm, e.g. microinjection of DNA con-
structs directly into the nucleus, result in the most predomi-
nantly cytoplasmic localization. Determination of the effect of
4 Leliveld, S. R., Dame, R. T., Mommaas, M. A., Danen-van Oorschot,
A. A. A. M., Rohn, J. L., Noteborn, M. H. M., and Abrahams, J. P. (2003)
Nucleic Acids Res., in press.
5 A. A. A. M. Danen-van Oorschot, P. Voskamp, C. M. J. Seelen,
M. H. A. M. van Miltenburg, M. W. Bolk, S.W. Tait, J. G. R. Boesen-de
Cock, J. L. Rohn, J. Borst, and M. H. M. Noteborn, submitted for
publication.
FIG. 6. Transcription/translation inhibitors did not abrogate
Apoptin-induced cell death. A, Saos-2 cells were treated with inhib-
itors as indicated, microinjected with plasmid expressing GFP, and
co-injected with Dextran-rhodamine as a marker. The cells were ana-
lyzed for expression of GFP and presence of marker (Dex-Rhod) by
fluorescence microscopy. Images of representative cells are shown, and
the scale bar corresponds to 10 m. B, Saos-2 cells were treated with
inhibitors as indicated, then injected with recombinant MBP-Apoptin or
MBP or not injected, and analyzed by immunofluorescence microscopy
for presence of the proteins and nuclear morphology. The results are
given as the means of two independent experiments, and the error bars
represent the standard deviations (n  30). Treatment without inhibi-
tor was done once.
FIG. 7.Apoptin does not act as a repressor of transcription.U-2
OS cells were transfected with different amounts of plasmids encoding
Apoptin or YY1 fused to the Gal4 BD or Gal4 BD alone as a control for
basal activity and 5xGal4-TK-Luc as a reporter. A LacZ plasmid was
co-transfected as a control for transfection efficiency. At day 2 post-
transfection, the lysates were made and analyzed for -galactosidase
and luciferase activity. The values shown are normalized for -galacto-
sidase and represent three independent experiments, each performed in
duplicate. The error bars represent the standard deviations.
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activation of stress pathways on the localization of Apoptin in
normal cells could shed light on the mechanisms influencing
the localization of Apoptin. However, as reported here, nuclear
localization does not enable Apoptin to induce cell death in
normal cells, because fusion of a heterologous NLS to Apoptin
forces it into the nucleus of nontransformed cells but does not
result in induction of apoptosis. Consistent with these data,
microinjection of Apoptin protein into the nucleus of normal
diploid fibroblasts did not induce cell death either,3 and under
the stressful transfection conditions mentioned above, nuclear
Apoptin did not kill normal cells (data not shown). Therefore, it
appears that besides nuclear localization, one or more addi-
tional events are required for Apoptin to become active. Indeed,
our laboratory has recently shown that Apoptin is phosphoryl-
ated on its C terminus specifically in tumor cells. A gain-of-
function point mutation that mimics constitutive phosphoryla-
tion enabled Apoptin to translocate to the nucleus of normal
cells and induce apoptosis (36). However, a loss-of-function
mutation did not completely abolish the cell killing activity of
Apoptin, which is consistent with results found with N-termi-
nal Apoptin variants. This suggests that the mechanism un-
derlying tumor-specific cell killing involves more than phospho-
rylation alone. For this reason, it is conceivable that the two
distinct apoptosis domains within Apoptin act by at least two
different pathways.
Compartmentalization has been shown on many occasions to
play a regulatory role in apoptosis pathways. For example,
release of pro-apoptotic factors from the mitochondria (apo-
ptosis-inducing factor, cytochrome c, and Smac) (37–39) or
translocation of pro-apoptotic members of the Bcl-2 family from
the cytosol to the outer mitochondrial membrane (tBid, Bax,
and BAD) (40–42) both result in apoptosis induction. Based on
the data reported here, we hypothesize that Apoptin is retained
in the cytoplasm of nontransformed cells. In transformed cells,
phosphorylation of Apoptin may enable it to migrate into the
nucleus and induce apoptosis (36). Forcing Apoptin into the
nucleus of nontransformed cells without the proper phospho-
rylation would not result in apoptosis induction. Therefore, the
specificity for inducing cell death in transformed cells does not
lie in the nuclear localization per se but involves phosphoryla-
tion and/or other modifications of Apoptin that in turn influ-
ence its localization. It is of great interest to determine further
which factors or events enable Apoptin to become active in
transformed cells, e.g. binding to downstream proteins or
additional ways of modification, which may also tell us more
about the nature of transformation.
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